RadNet (RDNT)

• Market cap: $3.51B
• 1 day: -4.86%
• 5 days: -13.28%
• 1 month: -3.84%
• 3 months: -21.32%
• 6 months: -29.28%
• Year to date: -32.49%
• 1 year: -0.61%
• 5 years: 293.36%
• 10 years: 412.55%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.

Employees: 11,021

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

157% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 21

8% more funds holding

Funds holding: 298 [Q3] → 323 (+25) [Q4]

1.54% more ownership

Funds ownership: 84.72% [Q3] → 86.26% (+1.54%) [Q4]

5% more call options, than puts

Call options by funds: $7.22M | Put options by funds: $6.9M

3% more capital invested

Capital invested by funds: $4.35B [Q3] → $4.46B (+$112M) [Q4]

4% less repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 116

18% less funds holding in top 10

Funds holding in top 10: 11 [Q3] → 9 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 27% upside
• Avg. target: $66 40% upside
• High target: $74 56% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Truist Securities David Macdonald 60% 1-year accuracy 60 / 100 met price target	56% upside $74	Buy Maintained	11 Apr 2025
Barclays Andrew Mok 46% 1-year accuracy 26 / 57 met price target	27% upside $60	Overweight Maintained	24 Mar 2025
Raymond James John Ransom 40% 1-year accuracy 4 / 10 met price target	37% upside $65	Strong Buy Upgraded	5 Mar 2025